Related Experiment Video
Updated: May 23, 2026

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
[What reasonable applications for regional citrate anticoagulation in renal replacement therapy?]
S Kissling1, P Wilson, C Ridel
1Service de néphrologie et hypertension, Départment de médecine interne CHUV, Lausanne. sebastien.kissling@chuv.ch
Abstract:
Regional citrate anticoagulation of the extracorporeal circuits (CRA) experienced considerable growth over the past decade. This development is partly explained by the significant progresses made in the field of bioengineering. These allow a secure administration of citrate, while an increasing availability of ionized calcium measurement at the bedside allows reactivity in monitoring the treatment. An increasing severity of the medical condition of patients requiring blood purification treatment gives more contrast to the profile of patient who may benefit from a CRA. If some methods of renal replacement therapy are well suited to this mode of anticoagulation, others are, to date, only at the stage of development and are applied under close medical supervision.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Anticoagulant Drugs: Low-Molecular-Weight Heparins
